stockrowArcutis Biotherapeutics, Inc. (ARQT) vs Tango Therapeutics, Inc. (TNGX)
- Arcutis Biotherapeutics, Inc. ARQT 25.55 −5.37%
- Tango Therapeutics, Inc. TNGX 21.50 +3.02%
Arcutis Biotherapeutics, Inc. and Tango Therapeutics, Inc. are both Biotechnology companies. Arcutis Biotherapeutics, Inc. and Tango Therapeutics, Inc. are of similar size ($3.5B and $3.4B). Tango Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Arcutis Biotherapeutics, Inc. trades at 119×. Arcutis Biotherapeutics, Inc. grew revenue faster over the last twelve months: 60.0% against 48.3%. Arcutis Biotherapeutics, Inc. has the higher net margin (5.88% vs 0.00%) and the higher return on invested capital (23.5% vs −808.4%). Across the 17 metrics below, Arcutis Biotherapeutics, Inc. leads on 12 and Tango Therapeutics, Inc. on 5.
Valuation
Profitability
| Metric | ARQT | TNGX | Biotechnology median |
|---|---|---|---|
| Gross margin | 91.18% | 100.00% | 65.16% |
| Operating margin | 6.91% | 0.00% | 0.00% |
| Net margin | 5.88% | 0.00% | 0.00% |
| Free cash flow margin | 11.74% | 0.00% | 0.00% |
| Return on equity | 14.88% | (21.34%) | (50.12%) |
| Return on assets | 6.68% | (18.86%) | (45.60%) |
| Return on invested capital | 23.48% | (808.35%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack